keyword
https://read.qxmd.com/read/38578213/cd3-and-cd8-t-cell-based-immune-cell-score-as-a-prognostic-factor-in-clear-cell-renal-cell-carcinoma
#1
JOURNAL ARTICLE
Jonne Åkerla, Olli Helminen, Juha P Väyrynen, Anne Parkkinen, Hilma Järvenpää, Jan Böhm, Maarit Ahtiainen, Heikki Seikkula
BACKGROUND AND PURPOSE: Immunoscore® is a prognostic parameter based on densities of lymphocyte populations in the tumor center and invasive margin. Immunoscore® is validated in colorectal cancer as a high Immunoscore® is associated with longer survival. Previous studies have suggested that Immunoscore® may also predict oncological outcomes in clear-cell renal cell carcinoma (ccRCC). This study aims to assess the prognostic role of immune cell score in ccRCC. MATERIAL AND METHODS: All patients with ccRCC undergoing surgery between 2007 and 2020 in Central Finland Central Hospital were retrospectively identified...
March 28, 2024: Acta Oncologica
https://read.qxmd.com/read/38577454/prognostic-and-predictive-role-of-immune-microenvironment-in-colorectal-cancer
#2
REVIEW
Olesya Kuznetsova, Mikhail Fedyanin, Larisa Zavalishina, Larisa Moskvina, Olga Kuznetsova, Alexandra Lebedeva, Alexey Tryakin, Galina Kireeva, Gleb Borshchev, Sergei Tjulandin, Ekaterina Ignatova
Colorectal cancer (CRC) represents a molecularly heterogeneous disease and one of the most frequent causes of cancer-related death worldwide. The traditional classification of CRC is based on pathomorphological and molecular characteristics of tumor cells (mucinous, ring-cell carcinomas, etc. ), analysis of mechanisms of carcinogenesis involved (chromosomal instability, microsatellite instability, CpG island methylator phenotype) and mutational statuses of commonly altered genes (KRAS, NRAS, BRAF, APC, etc...
March 15, 2024: World Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38552622/real-time-glioblastoma-tumor-microenvironment-assessment-by-spidermass-for-improved-patient-management
#3
JOURNAL ARTICLE
Yanis Zirem, Léa Ledoux, Lucas Roussel, Claude Alain Maurage, Pierre Tirilly, Émilie Le Rhun, Bertrand Meresse, Gargey Yagnik, Mark J Lim, Kenneth J Rothschild, Marie Duhamel, Michel Salzet, Isabelle Fournier
Glioblastoma is a highly heterogeneous and infiltrative form of brain cancer associated with a poor outcome and limited therapeutic effectiveness. The extent of the surgery is related to survival. Reaching an accurate diagnosis and prognosis assessment by the time of the initial surgery is therefore paramount in the management of glioblastoma. To this end, we are studying the performance of SpiderMass, an ambient ionization mass spectrometry technology that can be used in vivo without invasiveness, coupled to our recently established artificial intelligence pipeline...
March 22, 2024: Cell reports medicine
https://read.qxmd.com/read/38538574/adjuvant-nivolumab-capecitabine-or-the-combination-in-patients-with-residual-triple-negative-breast-cancer-the-oxel-randomized-phase-ii-study
#4
RANDOMIZED CONTROLLED TRIAL
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints included the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes...
March 27, 2024: Nature Communications
https://read.qxmd.com/read/38537969/cd8-positive-t-cell-infiltration-with-human-leukocyte-antigen-class-1-expression-predicts-patients-with-stage-iv-colorectal-cancer-survival
#5
MULTICENTER STUDY
Tetsuta Satoyoshi, Yoshihiko Hirohashi, Koichi Okuya, Masaaki Miyo, Emi Akizuki, Masayuki Ishii, Ryo Miura, Terufumi Kubo, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Ichiro Takemasa, Toshihiko Torigoe
BACKGROUND/AIM: The immune microenvironment in cancer correlates with cancer progression and patient prognosis. Cancer immune microenvironment evaluation, based on CD3+ and CD8+ T cell infiltration at the center and invasive margin of the tumor, is defined as the immunoscore. An international multicenter analysis revealed that the immunoscore can accurately predict the prognosis of patients with colorectal cancer (CRC) (stage I, II, and III). However, no markers are currently available to predict the prognosis in patients with stage IV CRC...
April 2024: Anticancer Research
https://read.qxmd.com/read/38523233/immunochemistry-based-quantification-of-tumor-infiltrating-lymphocytes-and-immunoscore-as-prognostic-biomarkers-in-bladder-cancer
#6
JOURNAL ARTICLE
Sarra Ben Rejeb, Sirine Elfekih, Nadia Kouki, Rami Boulma, Hassen Khouni
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) and the derived immunoscore (IS) have gained considerable attention over the last decade as prognostic markers in many solid cancers. However, in bladder cancer (BC), their prognostic value is not clearly established. METHODS: The present study aimed to quantify the TILs rates in BC, assess the derived immunoscore, and investigate their prognostic value. An immunochemistry-based quantification of the different subtypes of TILS was performed on paraffin-embedded blocks from patients with invasive urothelial carcinoma of the bladder...
March 25, 2024: Journal of the Egyptian National Cancer Institute
https://read.qxmd.com/read/38484206/prognostic-and-predictive-value-of-immunoscore-in-stage-iii-colorectal-cancer-pooled-analysis-of-cases-from-the-scot-and-idea-horg-studies
#7
JOURNAL ARTICLE
Enric Domingo, Caroline Kelly, Jennifer Hay, Owen Sansom, Noori Maka, Karin Oien, Tim Iveson, Mark Saunders, Rachel Kerr, Ian Tomlinson, Joanne Edwards, Andrea Harkin, Marta Nowak, Viktor Koelzer, Alistair Easton, Ioannis Boukovinas, Eleni Moustou, Ippokratis Messaritakis, Maria Chondrozoumaki, Michaela Karagianni, Franck Pagès, Fanny Arnoux, Christelle Lautard, Yoann Lovera, Isabelle Boquet, Aurélie Catteau, Jérôme Galon, Ioannis Souglakos, David N Church
PURPOSE: Immunoscore (IS) is prognostic in stage III colorectal cancer (CRC) and may predict benefit of duration (6 v 3 months) of adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. We sought to determine IS prognostic and predictive value in stage-III CRC treated with adjuvant FOLFOX or oral capecitabine and infusional oxaliplatin (CAPOX) in the SCOT and IDEA-HORG trials. METHODS: Three thousand sixty-one cases had tumor samples, of which 2,643 (1,792 CAPOX) were eligible for IS testing...
March 14, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38473874/clinical-relevance-of-tumour-infiltrating-immune-cells-in-her2-negative-breast-cancer-treated-with-neoadjuvant-therapy
#8
JOURNAL ARTICLE
Cristina Arqueros, Alberto Gallardo, Silvia Vidal, Rubén Osuna-Gómez, Ariadna Tibau, Olga Lidia Bell, Teresa Ramón Y Cajal, Enrique Lerma, Bárbara Lobato-Delgado, Juliana Salazar, Agustí Barnadas
Currently, therapy response cannot be accurately predicted in HER2-negative breast cancer (BC). Measuring stromal tumour-infiltrating lymphocytes (sTILs) and mediators of the tumour microenvironment and characterizing tumour-infiltrating immune cells (TIICs) may improve treatment response in the neoadjuvant setting. Tumour tissue and peripheral blood samples were retrospectively collected from 118 patients, and sTILs were evaluated. Circulating exosomes and myeloid-derived suppressor cells were determined by flow cytometry...
February 23, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38397905/significance-of-the-galectin-8-immunohistochemical-profile-in-ovarian-cancer
#9
JOURNAL ARTICLE
Elena-Roxana Avădănei, Irina-Draga Căruntu, Cornelia Amalinei, Ioana Păvăleanu, Simona-Eliza Giușcă, Andreea Rusu, Ludmila Lozneanu
Ovarian cancer (OC) still registers a high prevalence in female gynecological pathology. Given the aggressiveness of the tumor and the lack of response to conventional therapies, a current research interest is the identification of new prognostic markers. Gal-8, a member of the galectin family of molecules, involved in tumorigenesis, disease progression, and metastasis, has been assigned as a valuable tumor prognostic factor, and its inhibition may open new perspectives in cancer therapeutic management. Few studies have been carried out so far to evaluate OCs' galectin profiles...
January 28, 2024: Biomedicines
https://read.qxmd.com/read/38380081/kif26b-and-creb3l1-derived-from-immunoscore-could-inhibit-the-progression-of-ovarian-cancer
#10
JOURNAL ARTICLE
Shanshan Cong, Yao Fu, Xibo Zhao, Qiuyan Guo, Tian Liang, Di Wu, Jing Wang, Guangmei Zhang
BACKGROUND: Ovarian cancer (OV) is characteristic of high incidence rate and fatality rate in the malignant tumors of female reproductive system. Researches on pathogenesis and therapeutic targets for OV need to be continued. This study mainly analyzed the immune-related pathogenesis and discovered the key immunotherapy targets for OV. METHODS: WGCNA was used for excavating hub gene modules and hub genes related to the immunity of OV. Enrichment analysis was aimed to analyze the related pathways of hub gene modules...
2024: Journal of Immunology Research
https://read.qxmd.com/read/38361487/the-spatial-landscape-of-t-cells-in-the-microenvironment-of-stage-iii-lung-adenocarcinoma
#11
JOURNAL ARTICLE
Ziqing Zeng, Weijiao Du, Fan Yang, Zhenzhen Hui, Yunliang Wang, Peng Zhang, Xiying Zhang, Wenwen Yu, Xiubao Ren, Feng Wei
This study aimed to provide more information for prognostic stratification for patients through an analysis of the T-cell spatial landscape. It involved analyzing stained tissue sections of 80 patients with stage III lung adenocarcinoma (LUAD) using multiplex immunofluorescence and exploring the spatial landscape of T cells and their relationship with prognosis in the center of the tumor (CT) and invasive margin (IM). In this study, multivariate regression suggested that the relative clustering of CT CD4+ conventional T cell (Tconv) to inducible Treg (iTreg), natural regulatory T cell (nTreg) to Tconv, terminal CD8+ T cell (tCD8) to helper T cell (Th), and IM Treg to tCD8 and the relative dispersion of CT nTreg to iTreg, IM nTreg to nTreg were independent risk factors for DFS...
February 16, 2024: Journal of Pathology
https://read.qxmd.com/read/38307574/prognostic-value-of-immune-cells-subsets-within-the-tumor-microenvironment-in-patients-with-rectal-adenocarcinoma
#12
JOURNAL ARTICLE
Tao-Wei Ke, Senamile Temhlanga Zwane, Shu-Fen Chiang, Tsung-Wei Chen, Pei-Chen Yang, Liang-Chi Chen, Yun-Shan Lin, William Tzu-Liang Chen, K S Clifford Chao, Kevin Chih-Yang Huang
BACKGROUND/AIM: One-third of newly diagnosed colorectal cancer cases are rectal cancers. Multimodal treatment regimens including surgery, radiotherapy, and chemotherapy improve local control and survival outcome and decrease tumor relapse for patients with rectal adenocarcinoma (READ). However, stratification of patients to predict their responses is urgently needed to improve therapeutic responses. PATIENTS AND METHODS: Immunostainings of CD3+ , CD8+ , and CD45RO+ immune cell subsets within the tumor microenvironment were evaluated using immunohistochemistry in two hundred seventy-nine READ patients...
February 2024: Anticancer Research
https://read.qxmd.com/read/38301689/multiplex-analysis-of-intratumoural-immune-infiltrate-and-prognosis-in-patients-with-stage-ii-iii-colorectal-cancer-from-the-scot-and-quasar-2-trials-a-retrospective-analysis
#13
JOURNAL ARTICLE
Anja L Frei, Anthony McGuigan, Ritik R A K Sinha, Faiz Jabbar, Luciana Gneo, Tijana Tomasevic, Andrea Harkin, Tim Iveson, Mark P Saunders, Karin A Oien, Noori Maka, Francesco Pezzella, Leticia Campo, Molly Browne, Mark Glaire, Wanja Kildal, Havard E Danielsen, Jennifer Hay, Joanne Edwards, Owen Sansom, Caroline Kelly, Ian Tomlinson, Rachel Kerr, David Kerr, Enric Domingo, David N Church, Viktor H Koelzer
BACKGROUND: Tumour-infiltrating CD8+ cytotoxic T cells confer favourable prognosis in colorectal cancer. The added prognostic value of other infiltrating immune cells is unclear and so we sought to investigate their prognostic value in two large clinical trial cohorts. METHODS: We used multiplex immunofluorescent staining of tissue microarrays to assess the densities of CD8+ , CD20+ , FoxP3+ , and CD68+ cells in the intraepithelial and intrastromal compartments from tumour samples of patients with stage II-III colorectal cancer from the SCOT trial (ISRCTN59757862), which examined 3 months versus 6 months of adjuvant oxaliplatin-based chemotherapy, and from the QUASAR 2 trial (ISRCTN45133151), which compared adjuvant capecitabine with or without bevacizumab...
February 2024: Lancet Oncology
https://read.qxmd.com/read/38298428/prognostic-value-of-a-modified%C3%A2-immune-scoring-system-in-patients-with-pathological-t4-colorectal-cancer
#14
JOURNAL ARTICLE
Gendensuren Dorjkhorloo, Bilguun Erkhem-Ochir, Takuya Shiraishi, Makoto Sohda, Haruka Okami, Arisa Yamaguchi, Ikuma Shioi, Chika Komine, Nobuhiro Nakazawa, Naoya Ozawa, Yuta Shibasaki, Takuhisa Okada, Katsuya Osone, Akihiko Sano, Makoto Sakai, Hiroomi Ogawa, Takehiko Yokobori, Ken Shirabe, Hiroshi Saeki
Tumor-infiltrating immune cells, such as lymphocytes and macrophages, have been associated with tumor aggressiveness, prognosis and treatment response in colorectal cancer (CRC). An immune scoring system, Immunoscore (IS), based on tumor-infiltrating T cells in stage I-III CRC, was used to predict prognosis. An alternative immune scoring signature of immune activation (SIA) reflects the balance between anti- and pro-tumoral immune components. The present study aimed to evaluate the prognostic value of modified IS (mIS) and modified SIA (mSIA) in locally advanced pathological T4 (pT4) CRC, including stage IV CRC...
March 2024: Oncology Letters
https://read.qxmd.com/read/38285969/erratum-international-validation-of-the-immunoscore-biopsy-in-patients-with-rectal-cancer-managed-by-a-watch-and-wait-strategy
#15
(no author information available yet)
No abstract text is available yet for this article.
January 29, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38248122/artemis-as-predictive-biomarker-of-responsiveness-to-preoperative-chemoradiotherapy-in-patients-with-locally-advanced-rectal-cancer
#16
JOURNAL ARTICLE
Hai Liu, Runying Huang, Jingjing Shan, Xuyun Xie, Chongwei Wang, Peng Hu, Xiaonan Sun
The aim of this study was to identify Artemis as a predictive biomarker for guiding preoperative chemoradiotherapy in locally advanced rectal cancer. The resection specimens were collected from 50 patients with rectal cancer who underwent preoperative chemoradiotherapy. Artemis expression in biopsy tissues was evaluated using immunohistochemical staining according to the percentage of positively stained cells combined with staining intensity. Among the 50 patients, 36 (72%) had a weakly positive Artemis protein expression, 10 (20%) had a moderately positive expression, and 4 (8%) showed a strongly positive expression...
January 18, 2024: Current Oncology
https://read.qxmd.com/read/38223688/a-noninvasive-approach-to-evaluate-tumor-immune-microenvironment-and-predict-outcomes-in-hepatocellular-carcinoma
#17
JOURNAL ARTICLE
Jianmin Wu, Wanmin Liu, Xinyao Qiu, Jing Li, Kairong Song, Siyun Shen, Lei Huo, Lu Chen, Mingshuang Xu, Hongyang Wang, Ningyang Jia, Lei Chen
UNLABELLED: It is widely recognized that tumor immune microenvironment (TIME) plays a crucial role in tumor progression, metastasis, and therapeutic response. Despite several noninvasive strategies have emerged for cancer diagnosis and prognosis, there are still lack of effective radiomic-based model to evaluate TIME status, let alone predict clinical outcome and immune checkpoint inhibitor (ICIs) response for hepatocellular carcinoma (HCC). In this study, we developed a radiomic model to evaluate TIME status within the tumor and predict prognosis and immunotherapy response...
December 2023: Phenomics
https://read.qxmd.com/read/38202141/prognostic-implications-of-intratumoral-budding-in-colorectal-cancer-detailed-analysis-based-on-tumor-infiltrating-lymphocytes
#18
JOURNAL ARTICLE
Jung-Soo Pyo, Ji Eun Choi, Nae Yu Kim, Kyueng-Whan Min, Dong-Wook Kang
BACKGROUND: This study aims to understand the clinical and pathological importance of intratumoral budding (ITB) in colorectal cancer (CRC) and its relationship with tumor-infiltrating lymphocytes (TILs). CRCs can be classified into hot (high immunoscore (IS)) and cold (low IS) tumors. METHODS: We investigated the number of ITBs in a hotspot area and categorized them into high-ITB (≥5) and low-ITB (<5) groups. The clinicopathological significance of ITB in human CRCs was evaluated, and a detailed analysis based on tumor-infiltrating lymphocytes (TILs) was also performed...
December 26, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/38143911/predicting-t-cell-inflamed-gene-expression-profile-in-hepatocellular-carcinoma-based-on-dynamic-contrast-enhanced-ultrasound-radiomics
#19
JOURNAL ARTICLE
Yijie Wang, Weixiang Weng, Ruiming Liang, Qian Zhou, Hangtong Hu, Mingde Li, Lida Chen, Shuling Chen, Sui Peng, Ming Kuang, Han Xiao, Wei Wang
PURPOSE: The T cell-inflamed gene expression profile (GEP) quantifies 18 genes' expression indicative of a T-cell immune tumor microenvironment, playing a crucial role in the immunotherapy of hepatocellular carcinoma (HCC). Our study aims to develop a radiomics-based machine learning model using contrast-enhanced ultrasound (CEUS) for predicting T cell-inflamed GEP in HCC. METHODS: The primary cohort of HCC patients with preoperative CEUS and RNA sequencing data of tumor tissues at the single center was used to construct the model...
2023: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/38105958/adjuvant-nivolumab-capecitabine-or-the-combination-in-patients-with-residual-triple-negative-breast-cancer-the-oxel-randomized-phase-ii-study
#20
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints include the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes...
December 4, 2023: medRxiv
keyword
keyword
41559
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.